Erik H Knelson

9PUBLICATIONS
100CO-AUTHORS
Tumour immunologyMolecular targetsGene and molecular therapyHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Oct 29, 2026
A First-in-Human, Phase I Trial of MK-6598, an Inhibitor of the Immune Checkpoint IL4I1, With or Without Pembrolizumab for Advanced Solid Tumors.

|Aug 23, 2024
Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer.

Takahiko Murayama, Navin R Mahadevan, Catherine B Meador

|Sep 06, 2022
MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer.

Ryohei Yoshida, Maria Saigi, Tetsuo Tani

|Jul 27, 2022
Engineered Microphysiological Systems for Testing Effectiveness of Cell-Based Cancer Immunotherapies.

Marco Campisi, Sarah E Shelton, Minyue Chen

|Jul 05, 2022
STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models.

Gilles Berger, Erik H Knelson, Jorge L Jimenez-Macias

|Jun 09, 2022
Activation of Tumor-Cell STING Primes NK-Cell Therapy.

Erik H Knelson, Elena V Ivanova, Mubin Tarannum

Pageof 2

Frequent Collaborators

4 joint publications

Patrick H Lizotte

4 joint publications

David A Barbie

4 joint publications

Israel Cañadas

3 joint publications

Tetsuo Tani